VERIGRAFT is a biotechnology company based in Göteborg that specializes in the development of personalized tissue-engineered grafts for transplantation. The company focuses on creating veins, arteries, nerves, and heart valves, with an emphasis on reducing the risk of rejection in tissue transplantation. This innovative approach aims to enhance the compatibility of donated tissues with patients' own biological systems, potentially improving transplant outcomes.
Recently, VERIGRAFT completed Phase I/II clinical trials and has received regulatory approval for these trials, marking significant progress in their research and development efforts. The company has also been recognized for its contributions to the field, winning Business Sweden’s Catalyst Program in 2025. Their commitment to addressing previously incurable diseases reflects a strategic focus on advancing transplantation practices through innovative technology and ongoing clinical updates.